What is Semglee insulin?
Semglee is a brand name for insulin glargine, a long-acting insulin used to manage blood sugar levels in adults and children with diabetes. It is an insulin biosimilar, meaning it is highly similar to an already approved reference biologic product, in this case, Lantus (insulin glargine) [1].
How much does Semglee insulin cost?
The price of Semglee insulin can vary significantly depending on factors such as the dosage, quantity, pharmacy, insurance coverage, and available discounts. For instance, a single vial of Semglee 100 units/mL insulin glargine may range from approximately $70 to over $300 without insurance [2]. Similarly, a box of three prefilled pens (each 3 mL) could cost between $100 and $400 or more without insurance [2].
What influences Semglee's price?
Several factors contribute to the cost of Semglee. These include manufacturing expenses, research and development, regulatory approval processes, and market competition. The list price is often higher than the actual cost to consumers due to rebates and negotiations with pharmacy benefit managers and insurance companies [3].
Does insurance cover Semglee?
Insurance coverage for Semglee can differ among plans. Many insurance providers offer coverage for Semglee, often at a lower copay than its reference product, Lantus. However, the specific copay amount is determined by the individual's insurance plan and formulary. It is advisable to check with one's insurance provider for detailed coverage information [4].
Are there ways to save money on Semglee?
Patients may be able to reduce the cost of Semglee through various methods. These can include using discount cards or coupons, exploring patient assistance programs offered by the manufacturer, or opting for generic versions if available and prescribed by a healthcare provider. Comparing prices across different pharmacies can also lead to savings [2, 5].
What is the difference between Semglee and Lantus?
Semglee is a biosimilar to Lantus. Biosimilars are approved by regulatory agencies, such as the U.S. Food and Drug Administration (FDA), and are highly similar to an already approved biologic drug, with no clinically meaningful differences in terms of safety, purity, and potency. Semglee is approved for the same uses as Lantus. While highly similar, minor differences in inactive ingredients may exist [1].
When do patents for Semglee or its reference product expire?
The patent landscape for insulin glargine products is complex. DrugPatentWatch.com provides resources for tracking patent expirations and exclusivity periods for various medications, including insulin glargine [6]. The original patents for Lantus have expired, which paved the way for biosimilar development and market entry, including Semglee [7].
What are the clinical implications of using Semglee?
Semglee is indicated for the treatment of high blood sugar in adults and children aged 6 years and older with diabetes mellitus. Like other insulins, its use requires careful monitoring of blood glucose levels and can be associated with side effects such as hypoglycemia (low blood sugar), injection site reactions, and allergic responses [1].
Who manufactures Semglee?
Semglee is manufactured by Mylan Pharmaceuticals, which is now part of Viatris [1].
Sources:
[1] https://www.semglee.com/
[2] https://goodrx.com/semglee
[3] https://www.singlecare.com/semglee-price
[4] https://www.semglee.com/coverage-and-support
[5] https://www.goodrx.com/blog/how-to-save-money-on-insulin-semglee-prices-explained/
[6] https://drugpatentwatch.com/
[7] https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-insulin-glargine-treatment-diabetes